Novel unbiased equations to calculate triglyceriderich lipoprotein cholesterol from routine nonfasting lipids
 Michel P Hermans^{1, 3}Email author,
 Sylvie A Ahn^{2} and
 Michel F Rousseau^{2}
https://doi.org/10.1186/147528401356
© Hermans et al.; licensee BioMed Central Ltd. 2014
Received: 20 December 2013
Accepted: 19 February 2014
Published: 10 March 2014
Abstract
Background
Nonfasting triglyceriderich lipoproteins cholesterol (TRLC) contributes to cardiovascular risk, in that it includes remnant cholesterol (RC). TRLC is computed as total C  [LDLC + HDLC]. Such calculation applies only if LDLC is directly measured, or obtained from a nonFriedewald’s formula, a method as yet never benchmarked against independent markers of TRL burden.
Methods
The Discriminant Ratio (DR) methodology was used in 120 type 2 diabetic patients in order: (i) to compute TRLC from nonfasting lipids; (ii) to establish the performance of TRLC and TRLC/apoAI (vs. TGbased markers) to grade TRLs and atherogenic dyslipidemia (AD); and (iii) to relate TRLC with nonfasting TG.
Results
Depending on apoB_{100} availability, TRLC (mg/dL) can be derived from nonfasting lipids in two ways: (a) total cholesterol (TC)  [(0.0106 * TC  0.0036 * TG + 0.017 * apoB_{100}  0.27) * 38.6]  HDLC; and (b) TC  [(0.0106 * TC  0.0036 * TG + 0.017 * [0.65 * (TC  HDLC) + 6.3]  0.27) * 38.6]  HDLC. Discrimination between log[TG] and TRLC was similar (DR 0.94 and 0.84, respectively), whereas that of log[TG]/HDLC was better than TRLC/apoAI (DR 1.01 vs. 0.65; p 0.0482). All Pearson’s correlations between pairs reached unity, allowing formulation of two unbiased equivalence equations: (a) TRLC = 97.8 * log[TG]  181.9; and (b) TRLC/apoAI = 8.15 * (log[TG]/HDLC)  0.18.
Conclusions
TRLC and log[TG] are as effective and interchangeable for assessing remnant atherogenic particles. For grading TRLAD, it is best to use log[TG]/HDLC, inherently superior to TRLC/apoAI, while measuring the same underlying variable.
Keywords
Remnant cholesterol Triglycerides Nonfasting Chylomicrons Lipoprotein Diabetes Atherogenic dyslipidemiaIntroduction
Cholesterol (C) in atherogenic particles other than lowdensity lipoproteins (LDL) is an emerging risk factor (RF) for ischemic heart disease, and is mostly found in fasting and nonfasting triglyceriderich lipoproteins (TRLs). TRLs comprise two clusters: (i) chylomicrons (CM; triglycerides (TG)rich lipoproteins (TRLs) of intestinal origin) and their remnants (CMR), each carrying one apolipoprotein (apo) B_{48}); and (ii) verylow density lipoproteins (VLDL; endogenous TRLs which originate in the liver, and their relatively TGdepleted remnants (VLDLR), each carrying one apoB_{100}) [1–13].
Fasting and nonfasting lipid particles, triglyceriderich lipoproteins (TRL), and TRL remnants distribution, with respective contribution to total cholesterol, TRLcholesterol and TRLremnant cholesterol, alongside major corresponding apolipoprotein(s)
Fasting  Nonfasting  

All lipoproteins  Total cholesterol  Apolipoprotein(s)  All lipoproteins  Total cholesterol  Apolipoprotein(s) 
(CMR)  (CMRC)  (apoB_{48})  CM  CMC  apoB_{48} 
VLDL  VLDLC  apoB_{100}  CMR  CMRC  apoB_{48} 
VLDLR  VLDLRC  apoB_{100}  VLDL  VLDLC  apoB_{100} 
IDL  IDLC  apoB_{100}  VLDLR  VLDLRC  apoB_{100} 
LDL  LDLC  apoB_{100}  IDL  IDLC  apoB_{100} 
HDL  HDLC  apoAI; apoAII  LDL  LDLC  apoB_{100} 
Lipoprotein(a)  Lipoprotein(a)C  apoB_{100}; apo(a)  HDL  HDLC  apoAI; apoAII 
Lipoprotein(a)  Lipoprotein(a)C  apoB_{100}; apo(a)  
TRLs  TRLcholesterol  Apolipoprotein(s)  TRLs  TRLcholesterol  Apolipoprotein(s) 
(CMR)  (CMRC)  (apoB_{48})  CM  CMC  apoB_{48} 
VLDL  VLDLC  apoB_{100}  CMR  CMRC  apoB_{48} 
VLDLR  VLDLRC  apoB_{100}  VLDL  VLDLC  apoB_{100} 
VLDLR  VLDLRC  apoB_{100}  
TRL remnants  TRLremnant cholesterol  Apolipoproteins(s)  TRL remnants  TRLremnant cholesterol  Apolipoprotein(s) 
(CMR)  (CMRC)  (apoB_{48})  CMR  CMRC  apoB_{48} 
VLDLR  VLDLRC  apoB_{100}  VLDLR  VLDLRC  apoB_{100} 
Quantification of the cholesterol content of TGrich particles would be informative to better characterize their nonfasting atherogenic load. However this would require direct specific lipoproteins measurement beyond routine clinical practice. For this reason, several authors recently proposed to use a simple formula to measure “remnant cholesterol” (RC) from standard nonfasting lipids, “RC” being calculated as total C  (highdensitylipoprotein (HDL)C + LDLC) [10, 11]. Such equation however measures TRLC (the sum of CMC, CMRC, VLDLC and VLDLRC), and not RC. The latter is the sum of CMRC and VLDLRC, and accounts for only two out of four components of TRLC (Table 1).
As for RC, nonfasting TRLC is usually not measured, but derived according to the formula set out above: TRLC = total C minus [LDLC + HDLC] [8–11]. Whereas LDLC can be inferred from Friedewald’s equation in fasting conditions, this calculation underestimates LDLC in moderate to severe hypertriglyceridemia (200400 mg/dL), and is inapplicable for fasting TG >400 mg/dL [14]. To overcome this inaccuracy, a novel method for estimating LDLC from standard lipid profile using an adjustable factor for the TG:VLDLC ratio was recently proposed by Martin et al. [15, 16].
By its very nature, Friedewald’s equation is unusable in the nonfasting state. This is because in the presence of elevated fasting TG or in nonfasting conditions, the CtoTG content of remnant lipoproteins (RLPs) infringes the steady 1/5 ratio (20% C and 80% TG) at the core of Friedewald’s method [14–20]. Determining nonfasting TRLC using a Friedewaldderived LDLC level is methodologically inadequate, as it merely equates TRLC with onefifth of nonfasting TG, thus failing to provide additional information beyond TG levels [8, 10, 11].
The lack of a simple and suitable method to determine TRLC currently limits its clinical use for evaluating RVR, unless adequate alternatives to determine nonfasting LDLC are used. To circumvent this difficulty, an alternative approach is to derive LDLC from apoB_{100}, waiving the bias generated by applying a fixed CtoTG ratio that assumes constant and identical composition for all RLPs. A disadvantage of this method is the requirement for direct apoB_{100} measurement, limiting its use unless apoB_{100} is inferred from routine lipids, as previously described [17–21].
The aims of this study were: (i) to provide relevant equations to estimate TRLC from nonfasting lipids, regardless apoB_{100} availability; (ii) to establish the performance and equivalence of TGbased markers vs. TRLC and TRLC/apoAI, a continuous estimator of atherogenic dyslipidemia (AD); and (iii) to derive an unbiased equation predicting TRLC from nonfasting TG. We used the Discriminant Ratio (DR) methodology which standardizes comparisons between measurements by taking into account fundamental properties for assessing imprecision and practical performance of tests designed to quantify similar variables [19, 22, 23].
Methods
We studied 120 consecutive (86% white Caucasians) patients with T2DM, treated or not with lipidlowering drug(s) (LLD). Age; gender; diabetes duration; smoking history; anthropometric indices; hypertension and metabolic syndrome (MetS) prevalence, the latter defined according to the harmonized criteria of Alberti et al.[24]; habitual ethanol intake; current glucoselowering drugs, and LLDs were analysed. Hypertension was defined as systolic ≥140 and/or diastolic blood pressure ≥90 mmHg, and/or treatment with antihypertensive drugs. Glomerular filtration rate was estimated (eGFR) using the Modification of Diet in Renal Disease formula [25]. Albuminuria was defined as an albumin excretion ≥30 μg.mg creatinine^{1}.1.73 m^{2} from firstmorning sample. Coronary and peripheral artery disease (CAD and PAD) were diagnosed as in [26], while stroke was defined according to UK Prospective Diabetes Study (UKPDS) criteria [27]. Atherogenic dyslipidemia (AD) was defined according to [28–30].
The following variables were measured in the nonfasting state: glycated haemoglobin (HbA_{1c}), total C; HDLC; TG; apoAI and apoB_{100}, with total C and TG determined with SYNCHRON system (Beckman Coulter Inc., Brea, CA); HDLC with ULTRANgeneous reagent (Genzyme Corporation, Cambridge, MA); apoAI and apoB_{100} by immunonephelometry (BNII Analyzer, Siemens Healthcare Products GmbH, Marburg, Germany). Nonfasting routine lipids, apoAI and apoB_{100} were measured on two nonconsecutive days for DR calculation, with a 46 months’ interval between samples. A nonHDLC/apoB_{100} ratio >2.6 was an exclusion criterion because highly suggestive for Type III hyperlipoproteinemia [31]. The withinsubjects coefficients of variation were: 5.4% [total C]; 7.1% [HDLC]; 4.9% (apoAI) and 6.9% [apoB_{100}].
Normal TRLC values from 50 apparentlyhealthy lean Caucasians, untreated with LLD and without familial hypercholesterolemia or earlyonset parental CV disease, were (mg/dL): 24 (mean); 21 (median); 17 (SD); 2 (minimum); 71 (maximum); 13 (percentile 25) and 29 (percentile 75).
Each patient gave written informed consent; the study was performed in agreement with Helsinki’s Declaration; Good Clinical Practice principles; and the local Institutional Review Board.
Statistics
The Discriminant Ratio (DR) methodology compares different tests measuring the same underlying physiological variable by determining the ability of a test to discriminate between different subjects, and the comparison of discrimination between different tests as well as the underlying correlation between pairs of tests adjusting for attenuation due to withinsubject variation [22]. In a comparison study where duplicates measurements are performed in each subject, the measured betweensubject standard deviation (SD_{B}) is calculated as the SD of the subject mean values calculated from the 2 replicates.

The standard mathematical adjustment to yield the underlying betweensubject SD (SD_{U}) is: SD_{U} = √ (SD^{2}_{B}  SD^{2}_{W}/2);

The withinsubject variance (V_{w}) calculated (for m repeat tests) as (V_{w}) = Σ(x_{j} x_{i} )^{2}/(m1)), the withinsubject SD (SD_{w}) being its square root;

The DR represents the ratio SD_{U}/SD_{W}
Confidence limits for DR’s and the testing for equivalence of different DR’s were calculated and differences were considered significant for p < 0.05. Given sample size and number of replicates, the minimal detectable significant difference in DR for the present study was 0.42. Coefficients of correlation between pairs of tests (measured vs. estimated) were adjusted to include an estimate of the underlying correlation, as standard coefficients tend to underestimate the true correlation between tests, due to withinsubject variation [22].
Results are presented as means (±1 standard deviation [SD]), or as proportions (%). The significance of differences between means was assessed by Student’s t test, or by Welch’s test for data sets with significant differences in SDs, and by Chi^{2} test for differences in proportions. Results were considered statistically significant or nonsignificant (NS) for p <0.05 or p ≥0.05, respectively.
Results
Patients’ characteristics
n  120  

Age  Years  67 (11) 
Diabetes duration  Years  16 (9) 
Male: female  %  63: 37 
Smoking^{§}  424513  
Body mass index  kg.m^{2}  30.2 (5.6) 
Waist circumference  cm  106 (15) 
Metabolic syndrome  %  92 
Hypertension  %  89 
Antidyslipidemic drug(s)  %  92 
Statinfibrateezetimibe  %  813812 
HbA_{1c}  %  7.79 (1.32) 
HbA_{1c}  mmol.mol^{1}  62 (10) 
Glomerular filtration rate  mL.min^{1} 1.73 m^{2}  73 (27) 
Albuminuria  μg.mg creatinine^{1}  90 (240) 
Atherogenic dyslipidemia  %  58 
Total cholesterol  mg.dL^{1}  172 (34) 
NonHDLC  mg.dL^{1}  127 (33) 
LDLC  mg.dL^{1}  91 (26) 
TRLC  mg.dL^{1}  36 (20) 
TG  mg.dL^{1}  197 (101) 
log[TG]  mg.dL^{1}  2.23 (0.20) 
apoB_{100}  mg.dL^{1}  89 (21) 
apoAI  mg.dL^{1}  145 (25) 
HDLC  mg.dL^{1}  44 (12) 
log[TG]/HDLC  0.057 (0.024)  
TRLC/apoAI  0.28 (0.20)  
Macroangiopathy  %  33 
Coronary artery disease  %  23 
Peripheral artery disease  %  11 
Transient ischemic attack/stroke  %  7 
Most patients were on LLDs: statins (81%) and/or fibrates (38%). Current mean lipids and lipoproteins values were illustrative of patients with the usual form of T2DM, i.e. associated with central adiposity, insulin resistance (IR) and MetS: low HDLC with raised nonHDLC, apoB_{100}, TG and TRLC, together with a high prevalence of AD (58%). Overall macroangiopathy prevalence was 33%: CAD [23%]; PAD [11%] and/or cerebrovascular disease [7%].
Precision and discrimination of nonfasting TG, TRLC, and atherogenic dyslipidemia ratios expressed as betweensubject Standard Deviations (SD _{ u } ), global within subject Standard Deviation (SD _{ w } ), Discriminant Ratio (DR), and measured Pearson’s correlation coefficients between pairs of variables [adjusted for attenuation]
SD_{u}  SD_{w}  DR  CIs  p  Pearson’s coefficient  

log[TG]  0.161  0.171  0.94  [0.721.19]  0.5604  0.92  [1.00] 
TRLC  15.20  18.06  0.84  [0.611.09]  
log[TG]/HDLC  0.0198  0.0195  1.01  [0.791.27]  0.0482  0.89  [1.00] 
TRLC/apoAI  0.138  0.210  0.65  [0.400.90] 
The Pearson’s correlations between each pair of tests were high, respectively 0.92 (log[TG] vs. TRLC) and 0.89 (log[TG]/HDLC vs. TRLC/apoAI), each correlation reaching unity, once values were adjusted for attenuation prior to correlation (Table 3).
 1.apoB _{ 100 } is available alongside standard nonfasting lipids:$\begin{array}{ll}\mathbf{TRL}\mathbf{\u2012}\mathbf{C}=\mathbf{TC}& \left[\left(0.0106\phantom{\rule{0.5em}{0ex}}*\phantom{\rule{0.5em}{0ex}}\mathbf{TC}0.0036\phantom{\rule{0.5em}{0ex}}*\phantom{\rule{0.5em}{0ex}}\mathbf{TG}+0.017\right.\right.\\ \left.\left.*\phantom{\rule{0.5em}{0ex}}\mathbf{apo}{\mathbf{B}}_{\mathbf{100}}0.27\right)\phantom{\rule{0.5em}{0ex}}*\phantom{\rule{0.5em}{0ex}}38.6\right]\mathbf{HDL}\mathbf{\u2012}\mathbf{C}\end{array}$
 2.apoB _{ 100 } level is not available, and is computed according to [19]:$\begin{array}{ll}\mathbf{TRL}\mathbf{\u2012}\mathbf{C}=\mathbf{TC}& \left[\left(0.0106\phantom{\rule{0.5em}{0ex}}*\phantom{\rule{0.5em}{0ex}}\mathbf{TC}0.0036\phantom{\rule{0.5em}{0ex}}*\phantom{\rule{0.5em}{0ex}}\mathbf{TG}+0.017\right.\right.\\ \left.*\phantom{\rule{0.5em}{0ex}}\left[0.65\phantom{\rule{0.5em}{0ex}}*\phantom{\rule{0.5em}{0ex}}\left(\mathbf{TC}\mathbf{\u2012}\mathbf{HDL}\mathbf{\u2012}\mathbf{C}\right)+6.3\right]0.27\right)\\ \left.*\phantom{\rule{0.5em}{0ex}}38.6\right]\mathbf{HDL}\mathbf{\u2012}\mathbf{C}\end{array}$
Discussion
Measuring TG represents an easy means to estimate the combined mass of fasting or nonfasting TRLs, as surrogate for their cholesterol load. An excess of TRLs, including RLPs, throughout the nycthemeron epitomizes CMR conditions such the MetS, IR and the common form of T2DM. Elevated levels of TRLC contribute, alongside LDLC, to plaque formation and progression. TRLC is a modifiable driver of RVR. Whereas TG as such are not atherogenic, the welldemonstrated association between fasting or nonfasting TG and CVD is underlied by the atherogenicity of TRLs, especially that of RLPs [2–6, 8–11, 32, 33].
In fasting conditions, hypertriglyceridemia >150 mg/dL is categorized as “elevated” VLDL, corresponding to TRLC levels >30 mg/dL. Such assumption of equivalence is valid only if the composition of VLDL, in terms of C and TG, is in a ratio of 1/5. This is not necessarily the case in CMR states where nonVLDL TRLs (among which numerous RLPs) coexist alongside VLDL. Likewise, in nonfasting conditions, TRLs are further heterogeneous, in size and composition, being populated by various TGenriched and relatively TGdepleted lipoproteins (including remnants from the endogenous and exogenous pathways). The C/TG ratio of nonfasting TRLs substantially differs from that of fasting TRLs, the latter essentially consisting of standard VLDL with 20% cholesterol [1, 3, 13–17, 20, 21].
For this reason, recent articles on the usefulness of “RC” as residual risk marker relied by default on Friedewald’s formula to estimate the LDLC component of the equation. Doing so, their authors did not distinguish TRLC from RC. Such an oversimplification ascribes to RC all the observed risk of nonfasting TRLC. Besides, their rationale for extending the use of Friedewald’s equation to determine LDLC in nonfasting samples, in place of a direct assay, relied upon a linear relationship between calculated and measured LDLC in a reference subgroup, such a relationship being a selffulfilling prophecy [8, 10, 11, 14].
The present results provide unbiased and physiologicallyconsistent equations to determine TRLC from nonfasting lipids, regardless apoB_{100} availability. As expected, nonfasting TRLC and log[TG] were highly correlated, with adjusted Pearson’s coefficient reaching unity. Since both measures have uniform precision and discrimination, they provide similar information for ranking patients according to nonfasting TRLs, and are interchangeable. Yet, conceptually and educationally, determining TRLC as surrogate for TRLs is more attractive, since it quantifies the atherogenic component directly involved in driving CV risk, including all the cholesterol load from RLPs. In this context, the DR method provides an unbiased equivalence equation allowing to predict TRLC from log[TG], or viceversa.
While the concept of low HDLC as unconditional RF is strongly debated, the coexistence of elevated fasting TG together with low fasting HDLC allows identifying patients with AD, in whom residual risk is particularly high, even when onstatin LDLC is controlled [28–30, 33, 34]. An explanation for the accrued RVR from AD in the fasting state is that it could be a marker for high numbers of postprandial TRLs and elevated nonfasting TRLC. This is supported by results from an ACCORDLipid substudy, in which fenofibrate similarly lowered nonfasting TG in all T2DM participants, while reducing postprandial apoB_{48} excursions only in individuals with elevated fasting TG at baseline, a subgroup in which fenofibrate reduced CV outcomes [35].
In the presence of fasting hypertriglyceridemia (>150 mg/dL), the HDLC cutoffs defining AD (≤40 mg/dL [men] and ≤50 mg/dL [women]) are transposable to nonfasting conditions, because remnant TRLs have little influence on HDLC. Contrariwise, there are currently no standards or agreement defining (i) the upper physiological value for nonfasting TG; (ii) the sampling time after meal; and (iii) the lipid content and composition of the previous meal. For all these reasons we suggest to use either [TRLC/apoAI] or [log[TG]/HDLC] to assess postprandial AD as a continuous variable.
As the underlying correlation between TRLC and log[TG] on one hand, and between TRLC/apoAI and log[TG]/HDLC on the other hand, reached unity once preanalytical and analytical attenuation were taken into account, these two approaches may be used interchangeably to assess equivalent biological measures. While there was no significant difference between the discriminating performance of log[TG] compared to TRLC, the discrimination of the ratio log[(TG]/HDLC was clearly and significantly higher than the TRLC/apoAI ratio to quantify the severity of nonfasting AD in patients at high CMR. Given the perfect concordance between pairs of measurements, the clinician may prefer to expressing CV risk linked to TRLC (intuitively more educational than log[TG]), and to determine CV risk related to AD by calculating log[TG]/HDLC, which is superior to TRLC/apoAI. The latter has the inconvenience to require apoAI determination on top of routine lipids. Regarding biometric equivalence between atherogenicantiatherogenic ratios, we previously reported that nonHDLC/HDLC provides CV risk stratification similar to the apoB_{100}/apoAI ratio [36].
In this study, the performance of the above measures to that of a direct measurement of RC was not assessed, since the latter is not part of routine risk assessment. As regards cohort’s size, we compared the performance of two means to assess the burden of atherogenic TRL in 120 patients, an ample number given the DR methodology, which only requires ≥20 samples with 2 replicates as long as they represent a clinicallymeaningful range for the variable under study [see Appendix of[22]for a detailed discussion on sample size requirements for estimating DRs]. The fact that patients had T2DM in this study does not limit the applicability of the findings, since the metabolic and pathophysiological fundamentals of TRL, CMR and RC are similar in diabetic and nondiabetic subjects, at increasing levels along a continuum, from normal to impaired fasting glucose, and from prediabetes to T2DM [37, 38].
In conclusion, estimating TRLC requires formulas which reflect the complex compositional changes in nonfasting TRLs, the latter consisting of particles not exclusively generated along the VLDL pathway, in which TGcontent is heterogeneous and changes dynamically. We provide two unbiased equations to estimate the burden of TRLC based on routine nonfasting lipids, depending on apoB_{100} measurement availability. Our results show that TRLC and log[TG] are as effective and interchangeable to assess the atherogenic load of nonfasting TRLs. However, to grade TRLrelated AD, it is better to use log[TG]/HDLC, which is inherently superior to TRLC/apoAI, while measuring the same underlying variable.
Declarations
Authors’ Affiliations
References
 Cohn JS, Marcoux C, Davignon J: Detection, quantification, and characterization of potentially atherogenic triglyceriderich remnant lipoproteins. Arterioscler Thromb Vasc Biol. 1999, 19: 24742486. 10.1161/01.ATV.19.10.2474.View ArticlePubMedGoogle Scholar
 Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL: American Diabetes Association; American College of Cardiology foundation. Lipoprotein management in patients with cardiometabolic risk. Consensus statement from the American Diabetes Association and the American College of Cardiology foundation. Diabetes Care. 2008, 31: 811822. 10.2337/dc089018.View ArticlePubMedGoogle Scholar
 Fujioka Y, Ishikawa Y: Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb. 2009, 16: 145154. 10.5551/jat.E598.View ArticlePubMedGoogle Scholar
 Kannel WB, Vasan RS: Triglycerides as vascular risk factors: new epidemiologic insights. Curr Opin Cardiol. 2009, 24: 345350. 10.1097/HCO.0b013e32832c1284.PubMed CentralView ArticlePubMedGoogle Scholar
 Hermans MP, Fruchart JC: Reducing residual vascular risk in patients with atherogenic dyslipidaemia: where do we go from here?. Clin Lipidol. 2010, 5: 811826. 10.2217/clp.10.65.View ArticleGoogle Scholar
 Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J, Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration: Triglyceridemediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010, 375: 16341639.View ArticlePubMedGoogle Scholar
 Jacobson TA: Opening a new lipid “apothecary”: incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. Mayo Clin Proc. 2011, 86: 762780. 10.4065/mcp.2011.0128.PubMed CentralView ArticlePubMedGoogle Scholar
 Langsted A, Freiberg JJ, TybjaergHansen A, Schnohr P, Jensen GB, Nordestgaard BG: Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City heart study with 31 years of followup. J Intern Med. 2011, 270: 6575. 10.1111/j.13652796.2010.02333.x.View ArticlePubMedGoogle Scholar
 Jørgensen AB, FrikkeSchmidt R, West AS, Grande P, Nordestgaard BG, TybjærgHansen A: Genetically elevated nonfasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013, 34: 18261833. 10.1093/eurheartj/ehs431.View ArticlePubMedGoogle Scholar
 McPherson R: Remnant cholesterol: “Non(HDLC + LDLC)” as a coronary artery disease risk factor. J Am Coll Cardiol. 2013, 61: 437439. 10.1016/j.jacc.2012.11.009.View ArticlePubMedGoogle Scholar
 Varbo A, Benn M, TybjærgHansen A, Jørgensen AB, FrikkeSchmidt R, Nordestgaard BG: Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013, 61: 427436. 10.1016/j.jacc.2012.08.1026.View ArticlePubMedGoogle Scholar
 Zambon A, Puato M, Faggin E, Grego F, Rattazzi M, Pauletto P: Lipoprotein remnants and dense LDL are associated with features of unstable carotid plaque: a flag for nonHDLC. Atherosclerosis. 2013, 230: 106109. 10.1016/j.atherosclerosis.2013.06.024.View ArticlePubMedGoogle Scholar
 Fruchart JC, Duriez P: HDL and triglyceride as therapeutic targets. Curr Opin Lipidol. 2002, 13: 605616. 10.1097/0004143320021200000003.View ArticlePubMedGoogle Scholar
 Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18: 499502.PubMedGoogle Scholar
 Martin SS, Blaha MJ, Toth PP, Joshi PH, McEvoy JW, Ahmed HM, Elshazly MB, Swiger KJ, Michos ED, Kwiterovich PO, Kulkarni KR, Chimera J, Cannon CP, Blumenthal RS, Jones SR: Very large database of lipids: rationale and design. Clin Cardiol. 2013, 36: 641648. 10.1002/clc.22214.View ArticlePubMedGoogle Scholar
 Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, Jones SR: Comparison of a novel method vs the friedewald equation for estimating lowdensity lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013, 310: 20612068. 10.1001/jama.2013.280532.PubMed CentralView ArticlePubMedGoogle Scholar
 Planella T, Cortés M, MartínezBrú C, GonzálezSastre F, OrdóñezLlanos J: Calculation of LDLcholesterol by using apolipoprotein B for classification of nonchylomicronemic dyslipemia. Clin Chem. 1997, 43: 808815.PubMedGoogle Scholar
 Björkegren J, Karpe F, Milne RW, Hamsten A: Differences in apolipoprotein and lipid composition between human chylomicron remnants and very low density lipoproteins isolated from fasting and postprandial plasma. J Lipid Res. 1998, 39: 14121420.PubMedGoogle Scholar
 Hermans MP, Sacks FM, Ahn SA, Rousseau MF: NonHDLcholesterol as valid surrogate to apolipoprotein B_{100} measurement in diabetes: discriminant Ratio and unbiased equivalence. Cardiovasc Diabetol. 2011, 10: 2010.1186/147528401020.PubMed CentralView ArticlePubMedGoogle Scholar
 Bairaktari E, Hatzidimou K, Tzallas C, Vini M, Katsaraki A, Tselepis A, Elisaf M, Tsolas O: Estimation of LDL cholesterol based on the friedewald formula and on apo B levels. Clin Biochem. 2000, 33: 549555. 10.1016/S00099120(00)001624.View ArticlePubMedGoogle Scholar
 Martin SS, Blaha MJ, Elshazly MB, Brinton EA, Toth PP, McEvoy JW, Joshi PH, Kulkarni KR, Mize PD, Kwiterovich PO, Defilippis AP, Blumenthal RS, Jones SR: Friedewaldestimated versus directly measured lowdensity lipoprotein cholesterol and treatment implications. J Am Coll Cardiol. 2013, 62: 732739. 10.1016/j.jacc.2013.01.079.View ArticlePubMedGoogle Scholar
 Levy JC, Morris RJ, Hammersley M, Turner RC: Discrimination, adjusted correlation, and equivalence of imprecise tests: application to glucose tolerance. Am J Physiol. 1999, 276: E365E375.PubMedGoogle Scholar
 Hermans MP, Levy JC, Morris RJ, Turner RC: Comparison of insulin sensitivity tests across a range of glucose tolerance form normal to diabetes. Diabetologia. 1999, 42: 678687. 10.1007/s001250051215.View ArticlePubMedGoogle Scholar
 Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC: International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120: 16401645. 10.1161/CIRCULATIONAHA.109.192644.View ArticlePubMedGoogle Scholar
 Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999, 130: 461470. 10.7326/00034819130619990316000002.View ArticlePubMedGoogle Scholar
 Hermans MP, Ahn SA, Rousseau MF: The multifaceted outcomes of conjunct diabetes and cardiovascular familial history in type 2 diabetes. J Diabetes Complications. 2012, 26: 187194. 10.1016/j.jdiacomp.2012.03.014.View ArticlePubMedGoogle Scholar
 Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, Holman RR: UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective diabetes study risk engine. Stroke. 2002, 33: 17761781. 10.1161/01.STR.0000020091.07144.C7.View ArticlePubMedGoogle Scholar
 Hermans MP, Ahn SA, Rousseau MF: Log(TG)/HDLC is related to both residual cardiometabolic risk and βcell function loss in type 2 diabetes males. Cardiovasc Diabetol. 2010, 9: 8810.1186/14752840988.PubMed CentralView ArticlePubMedGoogle Scholar
 Hermans MP, Ahn SA, Rousseau MF: The atherogenic dyslipidemia ratio [log(TG)/HDLC] is associated with residual vascular risk, βcell function loss and microangiopathy in type 2 diabetes females. Lipids Health Dis. 2012, 11: 13210.1186/1476511X11132.PubMed CentralView ArticlePubMedGoogle Scholar
 Querton L, Buysschaert M, Hermans MP: Hypertriglyceridemia and residual dyslipidemia in statintreated, patients with diabetes at the highest risk for cardiovascular disease and achieving verylow lowdensity lipoproteincholesterol levels. J Clin Lipidol. 2012, 6: 434442. 10.1016/j.jacl.2012.04.002.View ArticlePubMedGoogle Scholar
 Murase T, Okubo M, Takeuchi I: NonHDLcholesterol/apolipoprotein B ratio: a useful distinguishing feature in the screening for type III hyperlipoproteinemia. J Clin Lipidol. 2010, 4: 99104. 10.1016/j.jacl.2010.01.004.View ArticlePubMedGoogle Scholar
 Hermans MP, Ahn SA, Rousseau MF, Zimering MB: Residual vascular risk in T2DM: the next frontier. Recent Advances in the Pathogenesis, Prevention and Management of Type 2 Diabetes and its Complications. 2011, Rijeka (Croatia): Intech, 4566.Google Scholar
 Bestehorn K, Smolka W, Pittrow D, Schulte H, Assmann G: Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statintreated patients in ambulatory care. Curr Med Res Opin. 2010, 26: 28332839. 10.1185/03007995.2010.532088.View ArticlePubMedGoogle Scholar
 Fruchart JC, Sacks FM, Hermans MP: International Steering Committee of R(3)i. Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i). Curr Med Res Opin. 2010, 26: 17931797. 10.1185/03007995.2010.489341.View ArticlePubMedGoogle Scholar
 ReyesSoffer G, Ngai CI, Lovato L, Karmally W, Ramakrishnan R, Holleran S, Ginsberg HN: Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care. 2013, 36: 422428. 10.2337/dc112556.PubMed CentralView ArticlePubMedGoogle Scholar
 Hermans MP, Ahn SA, Rousseau MF: The nonHDLC/HDLC ratio provides cardiovascular risk stratification similar to the ApoB/ApoA1 ratio in diabetics: Comparison with reference lipid markers. Diabetes Metab Syndr. 2007, 1: 2328. 10.1016/j.dsx.2006.11.003.View ArticleGoogle Scholar
 Tenenbaum A, Fisman EZ: Fibrates are an essential part of modern antidyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol. 2012, 11: 12510.1186/1475284011125.PubMed CentralView ArticlePubMedGoogle Scholar
 Fruchart JC, Davignon J, Hermans MP, AlRubeaan K, Amarenco P, Assmann G, Barter P, Betteridge J, Bruckert E, Cuevas A, Farnier M, Ferrannini E, Fioretto P, Genest J, Ginsberg HN, Gotto AM, Hu D, Kadowaki T, Kodama T, Krempf M, Matsuzawa Y, NúñezCortés JM, Monfil CC, Ogawa H, Plutzky J, Rader DJ, Sadikot S, Santos RD, Shlyakhto E, Sritara P, Sy R, Tall A, Tan CE, Tokgözoğlu L, Toth PP, Valensi P, Wanner C, Zambon A, Zhu J, Zimmet P: Residual risk reduction initiative (R3i). Residual macrovascular risk in 2013: what have we learned?. Cardiovasc Diabetol. 2014, 13: 2610.1186/147528401326.PubMed CentralView ArticlePubMedGoogle Scholar
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.